Regulation - BioMarin Pharmaceutical

Filter

Current filters:

BioMarin Pharmaceutical

Popular Filters

Positive CHMP opinion for BioMarin’s Vimizim for Morquio A syndrome

Positive CHMP opinion for BioMarin’s Vimizim for Morquio A syndrome

21-02-2014

BioMarin Pharmaceutical says that the European Medicines Agency’s Committee for Medicinal Products…

BioMarin PharmaceuticalEuropePharmaceuticalRare diseasesRegulationVimizim

FDA approves Vimizim to treat rare congenital enzyme disorder

FDA approves Vimizim to treat rare congenital enzyme disorder

17-02-2014

The US Food and Drug Administration on Friday (February 14) approved BioMarin Pharmaceutical’s Vimizim…

BioMarin PharmaceuticalNorth AmericaPharmaceuticalRare diseasesRegulationUSAVimizim

FDA committee recommends approval for BioMarin's Vimizim

FDA committee recommends approval for BioMarin's Vimizim

20-11-2013

A US Food and Drug Administration panel has voted in favor of approval of Vimizim for the treatment of…

BioMarin PharmaceuticalNorth AmericaPharmaceuticalRare diseasesRegulationUSAVimizim

BioMarin's Vimizim BLA accepted by FDA and MAA validated by EMA

30-05-2013

US drugmaker BioMarin Pharmaceutical (Nasdaq: BMRN) says that the Food and Drug Administration has accepted…

BioMarin PharmaceuticalEuropeNorth AmericaPharmaceuticalRare diseasesRegulationVimizim

BioMarin files BLA for Vimizim in USA

02-04-2013

US drugmaker BioMarin Pharmaceutical (Nasdaq: BMRN) has submitted a Biologics License Application (BLA)…

BioMarin PharmaceuticalBiotechnologyNorth AmericaRare diseasesRegulationVimizim

Scottish regulator backs restricted NHS use of Janssen's Zytiga; negative on BioMarin's Firdapse

13-08-2012

The Scottish Medicines Consortium (SMC) announced yesterday that it has accepted Johnson & Johnson (NYSE:…

BioMarin PharmaceuticalEuropeFirdapseJanssenJohnson & JohnsonOncologyPharmaceuticalPricingRare diseasesRegulationZytiga

Back to top